Zimbabwe has rejected a substantial US health deal valued at 367 million US dollars (272 million pounds) spanning five years due to Washington's insistence on sensitive data.
This move came to light following a government memo dated December was disclosed, which showed President Emmerson Mnangagwa believed the deal was "skewed".
An official spokesperson later stated that the United States was demanding access to genetic material for research and commercial gain while refused to guarantee the resulting advantages from future medical innovations.
"We will now turn to the challenging and unfortunate task of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had provided more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for continued dialogue to secure a deal suitable to all parties so the nation's vital HIV programme can continue.
Wider Context
This development follows a comparable case in Kenya, where a court blocked a related deal with the US after legal challenges were filed about the security of citizens' health data.
After resuming the presidency recently, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had overseen aid for the US government, but Trump stated its expenditure was "inefficient" and his government was pursuing government-to-government agreements to enhance openness and accountability.
As per reports, 16 nations in Africa have so far agreed to similar health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Declined Agreement
The funds for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment through American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Our nation was requested to share its biological resources and data for a long time, with no equivalent assurance of access to any medical innovations – like new medicines or tests – that could be developed from that shared data," he stated.
"Effectively, our nation would supply the basic resources for medical research without any certainty that the final treatments would be accessible to our population should a future disease outbreak emerge."
Sovereignty and International Frameworks
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were upending frameworks previously set up via the global organization.
The spokesperson cited its Pandemic Benefit-Sharing scheme designed to manage potential global health emergencies.
"This mechanism is designed to guarantee that when a nation provides its data, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the capability to develop them."
The government's concerns regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to continued dialogue with our US partners on how subsequent collaboration could be structured in a manner that respects the sovereignty and interests of each country."
Medical Community Response
Medical experts expressed it acknowledged the official position, but recommended that negotiations must proceed considering much of the country's Aids initiatives depended on external financing.
"Where technical issues exist, such as those relating to information security or implementation frameworks, these can often be addressed through detailed discussion and negotiated safeguards," it said.
The halted deal underscores the continuing tensions between receiving vital international aid and safeguarding national sovereignty in an ever more interconnected world.